Disease relevance of Zygomycosis

• CONCLUSIONS: Zygomycosis should be considered in immunosuppressed patients who develop sinusitis while receiving VRC prophylaxis, especially those with diabetes and malnutrition [1].
• Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis) [2].
• Posaconazole has shown promising clinical efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies-eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis [3].
• Risk factors for zygomycosis include uncontrolled diabetes mellitus, hematologic malignancies, corticosteroid therapy, deferoxamine therapy, intravenous drug use, and malnutrition [4].
• Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia [5].

High impact information on Zygomycosis

• Ketoconazole for subcutaneous phycomycosis [6].
• Posaconazole as salvage therapy for zygomycosis [7].
• Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice [8].
• BACKGROUND: Anecdotal evidence suggests a rise in zygomycosis in association with voriconazole (VRC) use in immunosuppressed patients [1].
• The efficacy of itraconazole in these models of zygomycosis suggests that this drug, as well as the new azole compounds presently under development, warrants close evaluation [9].

Chemical compound and disease context of Zygomycosis

• Activity of posaconazole in treatment of experimental disseminated zygomycosis [10].
• Breakthrough zygomycosis and voriconazole [11].
• In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis [12].
• The Center for Disease Control has received several other reports of zygomycosis traceable to the same material [13].
• This report and our literature review indicate that isolated renal zygomycosis can be associated with a favorable prognosis, occurs with greatest frequency in patients with AIDS, is associated with parenteral access, and may be managed by medical therapy alone [14].

Anatomical context of Zygomycosis

• Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor [15].
• These treatments increased the proportion of mice developing lethal phycomycosis of the central nervous system, and in the case of cortisone acetate, also promoted disseminated infection [16].
• Survival in cerebro-rhino-orbital zygomycosis and cavernous sinus thrombosis with combined therapy [17].

Gene context of Zygomycosis

• Disseminated zygomycosis associated with systemic lupus erythematosus [18].
• Diagnosis of disseminated zygomycosis using a polymerase chain reaction assay [19].
• Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants [20].
• Bull's-eye lesions of zygomycosis have been reported twice before [21].
• Total renal infarct and peri-renal abscess caused by phycomycosis (a case report) [22].

Analytical, diagnostic and therapeutic context of Zygomycosis

• Treatment of zygomycosis should consist of radical surgical debridement of the infected tissue, together with intensive broad-spectrum antimycotic therapy with amphotericin B [23].
• Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis [24].
• Indolent zygomycosis associated with deferoxamine chelation therapy [25].
• To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients) [26].

References